Attendo AB (publ) (ATT.ST)
SEK 60.9
(-2.25%)
SEK 60.9
(-2.25%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 17.53 Billion SEK | 1.19% |
| 2022 | 17.32 Billion SEK | 7.48% |
| 2021 | 16.11 Billion SEK | 6.04% |
| 2020 | 15.2 Billion SEK | 5.28% |
| 2019 | 14.43 Billion SEK | 91.22% |
| 2018 | 7.55 Billion SEK | 1.59% |
| 2017 | 7.43 Billion SEK | 45.66% |
| 2016 | 5.1 Billion SEK | 0.69% |
| 2015 | 5.06 Billion SEK | -29.48% |
| 2014 | 7.18 Billion SEK | 5.4% |
| 2013 | 6.81 Billion SEK | 15.03% |
| 2012 | 5.92 Billion SEK | -38.08% |
| 2011 | 9.57 Billion SEK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 20.03 Billion SEK | 8.3% |
| 2024 Q1 | 18.49 Billion SEK | 5.51% |
| 2024 Q3 | 19.67 Billion SEK | -1.78% |
| 2023 FY | 17.53 Billion SEK | 1.19% |
| 2023 Q1 | 18.47 Billion SEK | 6.66% |
| 2023 Q2 | 18.82 Billion SEK | 1.86% |
| 2023 Q4 | 17.53 Billion SEK | -3.56% |
| 2023 Q3 | 18.17 Billion SEK | -3.42% |
| 2022 Q1 | 16.65 Billion SEK | 3.32% |
| 2022 FY | 17.32 Billion SEK | 7.48% |
| 2022 Q4 | 17.32 Billion SEK | 2.02% |
| 2022 Q3 | 16.98 Billion SEK | -1.2% |
| 2022 Q2 | 17.18 Billion SEK | 3.2% |
| 2021 FY | 16.11 Billion SEK | 6.04% |
| 2021 Q3 | 15.79 Billion SEK | -2.33% |
| 2021 Q4 | 16.11 Billion SEK | 2.08% |
| 2021 Q1 | 16.09 Billion SEK | 5.89% |
| 2021 Q2 | 16.16 Billion SEK | 0.44% |
| 2020 FY | 15.2 Billion SEK | 5.28% |
| 2020 Q2 | 16.25 Billion SEK | 0.0% |
| 2020 Q3 | 16 Billion SEK | -1.51% |
| 2020 Q4 | 15.2 Billion SEK | -5.04% |
| 2020 Q1 | 16.25 Billion SEK | 12.56% |
| 2019 Q3 | 13.85 Billion SEK | -2.83% |
| 2019 Q4 | 14.43 Billion SEK | 4.2% |
| 2019 Q1 | 13.68 Billion SEK | 81.27% |
| 2019 FY | 14.43 Billion SEK | 91.22% |
| 2019 Q2 | 14.26 Billion SEK | 4.19% |
| 2018 Q2 | 7.96 Billion SEK | 2.97% |
| 2018 FY | 7.55 Billion SEK | 1.59% |
| 2018 Q3 | 7.74 Billion SEK | -2.76% |
| 2018 Q1 | 7.73 Billion SEK | 4.09% |
| 2018 Q4 | 7.55 Billion SEK | -2.53% |
| 2017 Q2 | 5.44 Billion SEK | 6.81% |
| 2017 Q3 | 5.48 Billion SEK | 0.77% |
| 2017 Q4 | 7.43 Billion SEK | 35.47% |
| 2017 FY | 7.43 Billion SEK | 45.66% |
| 2017 Q1 | 5.09 Billion SEK | -0.1% |
| 2016 Q4 | 5.1 Billion SEK | -2.02% |
| 2016 Q3 | 5.2 Billion SEK | 3.15% |
| 2016 Q1 | 4.94 Billion SEK | -2.39% |
| 2016 FY | 5.1 Billion SEK | 0.69% |
| 2016 Q2 | 5.04 Billion SEK | 2.06% |
| 2015 FY | 5.06 Billion SEK | -29.48% |
| 2015 Q4 | 5.06 Billion SEK | -28.54% |
| 2015 Q3 | 7.09 Billion SEK | 0.0% |
| 2015 Q1 | - SEK | -100.0% |
| 2014 Q4 | 7.18 Billion SEK | 0.0% |
| 2014 FY | 7.18 Billion SEK | 5.4% |
| 2013 FY | 6.81 Billion SEK | 15.03% |
| 2012 FY | 5.92 Billion SEK | -38.08% |
| 2011 FY | 9.57 Billion SEK | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Ambea AB (publ) | 12.97 Billion SEK | -35.127% |
| Humana AB (publ) | 7.1 Billion SEK | -146.762% |
| ProstaLund AB (publ) | 10.21 Million SEK | -171493.579% |